| Followers | 200 |
| Posts | 25597 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Saturday, March 30, 2024 12:27:25 PM
No, that’s not an FDA requirement. It’s an SEC requirement for 8-K’s. Receiving approval to market a drug from regulatory authorities like the MHRA or the FDA would generally be considered a material event that requires public disclosure under SEC regulations.
You’re going to hear about it. It is going to make news. How it is covered again, is often a function of the fact that typically media will focus on the researchers who did the study and often will at best bury a company name somewhere hard to find in an article. If it is a penny stock, they may not mention the company name at all. However, such rules typically do NOT apply in British press, international press or scientific press, where the name of the sponsor and how to get the drug are actually material information for their doctor / readers.
US press, they are anxious to avoid looking like they are promoting corporate interests. Business press won’t cover it unless there is an angle, like the lawsuit, maybe.
You’re going to hear about it. It is going to make news. How it is covered again, is often a function of the fact that typically media will focus on the researchers who did the study and often will at best bury a company name somewhere hard to find in an article. If it is a penny stock, they may not mention the company name at all. However, such rules typically do NOT apply in British press, international press or scientific press, where the name of the sponsor and how to get the drug are actually material information for their doctor / readers.
US press, they are anxious to avoid looking like they are promoting corporate interests. Business press won’t cover it unless there is an angle, like the lawsuit, maybe.
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
